title: [Novel conventional therapies in onco-hemathology].
abstract: Cytogenetic, molecular and phenotyping features of malignant hematologic diseases succeeded in improving their management by a more accurate stratification of patients according to several groups of risk and by providing a rational for targeted therapy. Three major types of treatment (excluding cellular therapy) are currently available in onco-hematology: conventional chemotherapy, small molecules for targeted therapy and monoclonal antibodies. Conventional chemotherapy with optimization of doses and multidrug-based regimens allowed to substantially improve survival of patients and keeps a place of choice in treatment of these diseases. Targeted treatments came from the cytogenetic and molecular characterization of hemopathies. Thus, the kinase Bcr-Abl, as a result of the translocation t(9;22)(q34;q11), has been successfully targeted by tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. Molecular abnormalities like internal-tandem duplication/point activating mutations in FLT3 in some acute myeloblastic leukemia or epigenetic dysregulations in some blood malignancies can also be targeted by small molecules. Hematopoietic malignant cells are phenotypically characterized by expression of cluster of differentiation (CD) on their surface. These CD are detected by flow cytometry using specific antibodies. Monoclonal antibodies targeting different CD have been developed for treatment. Rituximab, an anti-CD20 antibody, was the first monoclonal antibody successfully developed for treatment of malignant hematologic diseases. Since rituximab, many other monoclonal antibodies are being developed. Trends in malignant hematologic diseases presented here will include treatments, which have at least entered phase I/II clinical trials in adult or childhood leukemia. They include some novel drugs of conventional chemotherapy like second-generation nucleoside analogues. We will give an overview of the small molecules targeting the different cellular pathways and we will highlight those appearing as the most promising like novel TKIs. The large field of monoclonal antibodies will be also approached focusing on antibodies developed in leukemias.
authors.affiliation: Institut d'hématologie et oncologie pédiatrique, Hospices civils de Lyon, France. frederic.baleydier@chu-lyon.fr
authors.forename: Frédéric
authors.initials: F
authors.lastname: Baleydier
authors.forename: Carine
authors.initials: C
authors.lastname: Domenech
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
mesh_terms: D000227:Adenine Nucleotides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D000077866:Clofarabine; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D011684:Purine Nucleosides / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use
chemical_list: D000227:Adenine Nucleotides; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D011684:Purine Nucleosides; D011744:Pyrimidinones; C113101:forodesine; C104457:nelarabine; D000077866:Clofarabine